Uzuka Y, Saito Y
Cancer Treat Rep. 1985 Nov;69(11):1297-9.
Twenty-three patients with chronic myelogenous leukemia (CML) in terminal transformation were treated with a regimen incorporating vindesine (a new derivative of vinblastine), prednisolone, and additional cytarabine. Of 21 patients in blastic crisis, complete remission (CR) was achieved in 15 (71.4%). All of five patients with lymphoid morphology and ten of 12 with myeloid morphology (83.3%) achieved CR, while none of four with monocytoid morphology achieved CR. Two patients in accelerated phase also attained CR. Our results compare favorably with those of other regimens in this refractory disorder and indicate that the regimens incorporating vindesine, prednisolone, and additional cytarabine may be recommended in the treatment of CML-blastic crisis with both lymphoid and myeloid morphology and accelerated phase of CML as well.
23例处于终末期转化的慢性粒细胞白血病（CML）患者接受了包含长春地辛（长春碱的一种新衍生物）、泼尼松龙和额外阿糖胞苷的治疗方案。在21例处于急变期的患者中，15例（71.4%）获得完全缓解（CR）。5例具有淋巴细胞形态的患者和12例具有髓细胞形态的患者中的10例（83.3%）获得CR，而4例具有单核细胞形态的患者均未获得CR。2例处于加速期的患者也获得了CR。我们的结果与其他针对这种难治性疾病的治疗方案相比具有优势，表明包含长春地辛、泼尼松龙和额外阿糖胞苷的治疗方案可推荐用于治疗具有淋巴细胞和髓细胞形态的CML急变期以及CML加速期。
